Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S3-E48.1 - Results of Altimmune’s 12 week Phase 1B Study of Pemvidutide
Description: A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, Principal Investigator Stephen Harrison reviews the top-line results of Altimmune’s 12 week Phase 1B study of pemvidutide, a GLP-1/glucagon dual receptor agonist.Stephen describes the effects of pemvidutide on the liver’s fat creation and processing. “It's like taking a drug that both induces weight loss and increases exercise without actually having to diet or get out and exercise. So just think of this drug physiologically working in that particular manner.” He g...